Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
How patients with a rare liver disease respond to first-line therapy after just one year can predict their odds of serious complications — or death — over the next five years. A large real-world study found that PBC patients who responded to UDCA had significantly lower rates of liver failure and mortality, reinforcing the need to escalate treatment for nonresponders without delay.
For patients with primary biliary cholangitis (PBC) — a rare, chronic autoimmune liver disease — a biochemical response to first-line therapy at the 12-month mark is a powerful predictor of long-term outcomes, according to a new propensity-matched cohort study presented at the AASLD annual meeting in Denver.
Researchers analyzed data from over 147 million patients across 112 U.S. health systems, ultimately comparing matched cohorts of 2,911 PBC patients. Those who responded to ursodeoxycholic acid (UDCA) — defined by normalized alkaline phosphatase and bilirubin levels — fared significantly better over five years than nonresponders. The lead researcher's takeaway was direct: "We can check ALP and bilirubin at 1 year on UDCA," and clinicians should consider "escalating nonresponders without delay."
By the Numbers:
Why it matters: With FDA-approved second-line options like seladelpar and elafibranor now available for UDCA nonresponders, this study gives clinicians a clear, real-world validated signal to act on early — potentially preventing liver failure and death in a population that has historically had limited options.
